GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » DeferredTaxAndRevenue

MindBio Therapeutics (XCNQ:MBIO) DeferredTaxAndRevenue : C$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

MindBio Therapeutics's current deferred tax and revenue for the quarter that ended in Mar. 2024 was C$0.00 Mil.

MindBio Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for MindBio Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics DeferredTaxAndRevenue Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
DeferredTaxAndRevenue
- - 0.10

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.10 0.10 - -

MindBio Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

By Stock market mentor Stock market mentor 01-17-2023